LUCIUS 卢修斯 帕唑帕尼 Pazopanib晚期肾细胞癌

帕唑帕尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Pazopanib

老挝国家食药监局批准上市
老挝国家药检所检测认证

晚期肾细胞癌

Composition:
Each film-coated tablet contains Pazopanib

LUCIUS
HARMACEUTICALS

ue 216. mg equivalent to
Indication:
LuciPazo is a kinase inhibitor indicated for the
treatment of adults with:
.advanced renal cell carcinoma IRCC)

LUCIPazO

晚期软组织肉瘤

auvanced soft tissue sarcoma (STS) who have
Teceived prior chemotherany
Dosage and Use:

Pazopanib Tablets

Recommended Dosage: 800 mg orally once
datly withouf food fat les
ast hour before or

200mg

* Moderate Hepatic Impairment: 200 mg orally
once daily
Storage: in a dry place and store at 20C to 25°C.

120 Tablets

FDA批准

Warning:
Atep medicine out of reach of Children. Do no
er LuciPazo during Pregnancy and

PLEASESEEPACKAGE INSERT
Manufactured and Marketed by:

LUCIUS

权威认证

Thongmang village, Xaythany district
Vientiane Capital, Laos
Warning: Tobe sold by retail on nrescrintion
pysicians only, and as direeted
2 tne paysician

Rx only

口碑质量

应 症 :

帕唑帕尼是一种激酶抑制剂,适用于治疗患有以下疾病的成人:
1、晚期肾细胞癌(RCC)。
2、接受过化疗的晚期软组织肉瘤(STS)。

推荐剂量:

1、推荐剂量:每日口服一次,每次800mg,不与食物同时服用(饭前至少
1小时或饭后2小时)。
2、中度肝功能不全:每日口服一次,每次200mg。